Home Cart Sign in  
Chemical Structure| 1372540-25-4 Chemical Structure| 1372540-25-4

Structure of GSK2636771
CAS No.: 1372540-25-4

Chemical Structure| 1372540-25-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GSK2636771 is a potent, selective and orally bioavailable PI3Kβ inhibitor. It has been used in trials studying the treatment of CANCER, LYMPHOMA, Solid Neoplasm, Recurrent Solid Neoplasm, and Advanced Malignant Neoplasm, among others.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GSK2636771

CAS No. :1372540-25-4
Formula : C22H22F3N3O3
M.W : 433.42
SMILES Code : O=C(C1=C2C(N(CC3=CC=CC(C(F)(F)F)=C3C)C(C)=N2)=CC(N4CCOCC4)=C1)O
MDL No. :MFCD22417098
InChI Key :XTKLTGBKIDQGQL-UHFFFAOYSA-N
Pubchem ID :56949517

Safety of GSK2636771

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of GSK2636771

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110β

In Vitro:

Cell Line
Concentration Treated Time Description References
ZR75-1 1 μM 1 hour p110β inhibition delayed AKT phosphorylation PMC5449270
MDA-MB-415 1 μM 1 hour p110β inhibition delayed AKT phosphorylation PMC5449270
CAMA-1 1 μM 1 hour p110β inhibition delayed AKT phosphorylation PMC5449270
VTC-103 cells 25 μM 6 days Evaluate the synergistic inhibitory effect of GSK2636771 combined with αCT1 and TMZ on VTC-103 cells PMC8755794
U87MG cells 25 μM 6 days Evaluate the synergistic inhibitory effect of GSK2636771 combined with αCT1 and TMZ on U87MG cells PMC8755794
LN229 cells 25 μM 6 days Evaluate the synergistic inhibitory effect of GSK2636771 combined with αCT1 and TMZ on LN229 cells PMC8755794
EEC cell lines 1 μM/10 μM 72 hours No significant difference in cell viability following p110 β inhibition between PTEN -mutant and PTEN wild-type EEC cell lines was found, and a marked decrease in cell viability was only observed in the p110 β-reliant prostate and breast cancer cell lines. PMC3700760
N-TERT cells 1 µM 72 hours GSK2636771 slightly reduced the number of N-TERT cells but did not significantly affect cell viability. PMC8036316
IC8 cells 1 µM 72 hours GSK2636771 had a minor effect on the number and viability of IC8 cells. PMC8036316
Met1 cells 1 µM 72 hours GSK2636771 slightly reduced the number of Met1 cells but did not significantly affect cell viability. PMC8036316
HTLA cells 10 µM overnight To detect the agonist activity of GSK2636771 on GPR39 PMC5118639

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Braf-mutant, PTEN-null melanoma model Oral gavage 30 mg/kg Daily until the end of the experiment To evaluate the efficacy of GSK2636771 in combination with anti-OX40 antibody in treating PTEN-null melanoma. The results showed that the combination treatment significantly delayed tumor growth and extended the survival of mice. PMC7232853
Nude mice ZR75-1/FR xenograft model Oral 30 mg/kg/d daily for 4 weeks p110β inhibition induced tumor regression, but tumors resumed growth after 3 weeks, while combined p110α/β inhibition provided durable tumor regression PMC5449270
SCID/beige mice SF295 xenograft tumor model intraperitoneal injection 20 mg/kg every other day for 18 days Evaluate the synergistic inhibitory effect of GSK2636771 combined with αCT1 and TMZ on SF295 xenograft tumors PMC8755794

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01458067 Cancer PHASE1 COMPLETED 2016-02-25 GSK Investigational Site, New ... More >>Haven, Connecticut, 06520, United States|GSK Investigational Site, Oklahoma City, Oklahoma, 73104, United States|GSK Investigational Site, Nashville, Tennessee, 37203, United States|GSK Investigational Site, Salt Lake City, Utah, 84112, United States|GSK Investigational Site, Seoul, 110-744, Korea, Republic of|GSK Investigational Site, Seoul, 120/752, Korea, Republic of|GSK Investigational Site, Sutton, Surrey, SM2 5PT, United Kingdom|GSK Investigational Site, London, W1G 6AD, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.31mL

0.46mL

0.23mL

11.54mL

2.31mL

1.15mL

23.07mL

4.61mL

2.31mL

References

 

Historical Records

Categories